BLUE
Price:
$0.5289
Market Cap:
$101.94M
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment...[Read more]
Industry
Biotechnology
IPO Date
2013-06-19
Stock Exchange
NASDAQ
Ticker
BLUE
According to bluebird bio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 240.30M. This represents a change of -53.81% compared to the average of 520.26M of the last 4 quarters.
The mean historical Enterprise Value of bluebird bio, Inc. over the last ten years is 1.73B. The current 240.30M Enterprise Value has changed 1.29% with respect to the historical average. Over the past ten years (40 quarters), BLUE's Enterprise Value was at its highest in in the March 2019 quarter at 5.59B. The Enterprise Value was at its lowest in in the December 2013 quarter at 119.07M.
Average
1.73B
Median
1.34B
Minimum
-35656550.00
Maximum
4.42B
Discovering the peaks and valleys of bluebird bio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 231.98%
Maximum Annual Enterprise Value = 4.42B
Minimum Annual Increase = -3546.74%
Minimum Annual Enterprise Value = -35656550.00
Year | Enterprise Value | Change |
---|---|---|
2022 | 712.19M | 15.46% |
2021 | 616.83M | -61.87% |
2020 | 1.62B | -46.09% |
2019 | 3.00B | -3.07% |
2018 | 3.10B | -29.96% |
2017 | 4.42B | 231.98% |
2016 | 1.33B | -0.63% |
2015 | 1.34B | 8.99% |
2014 | 1.23B | -3546.74% |
2013 | -35656550.00 | -110.79% |
The current Enterprise Value of bluebird bio, Inc. (BLUE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
982.19M
5-year avg
1.81B
10-year avg
1.73B
bluebird bio, Inc.’s Enterprise Value is greater than Mersana Therapeutics, Inc. (138.92M), greater than Zentalis Pharmaceuticals, Inc. (217.53M), less than Y-mAbs Therapeutics, Inc. (539.42M), less than Travere Therapeutics, Inc. (1.21B), less than Madrigal Pharmaceuticals, Inc. (4.91B), less than Viking Therapeutics, Inc. (5.95B), less than Sarepta Therapeutics, Inc. (13.28B), greater than Hepion Pharmaceuticals, Inc. (2.24M), less than PTC Therapeutics, Inc. (2.17B), less than Agios Pharmaceuticals, Inc. (2.44B), less than Intercept Pharmaceuticals, Inc. (915.81M), greater than Karyopharm Therapeutics Inc. (201.87M), less than CureVac N.V. (0), less than Reata Pharmaceuticals, Inc. (390.67M), less than Krystal Biotech, Inc. (6.68B), less than Vir Biotechnology, Inc. (4.95B), less than Propanc Biopharma, Inc. (864.03M), greater than null (1.07M),
Company | Enterprise Value | Market cap |
---|---|---|
138.92M | $165.61M | |
217.53M | $210.48M | |
539.42M | $615.95M | |
1.21B | $839.88M | |
4.91B | $5.30B | |
5.95B | $6.00B | |
13.28B | $12.29B | |
2.24M | $4.20M | |
2.17B | $2.43B | |
2.44B | $2.46B | |
915.81M | $794.69M | |
201.87M | $91.04M | |
0 | $614.60M | |
390.67M | $6.57B | |
6.68B | $5.29B | |
4.95B | $1.06B | |
864.03M | $278.87K | |
1.07M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like bluebird bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like bluebird bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is bluebird bio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for bluebird bio, Inc. (BLUE)?
What is the 3-year average Enterprise Value for bluebird bio, Inc. (BLUE)?
What is the 5-year average Enterprise Value for bluebird bio, Inc. (BLUE)?
How does the current Enterprise Value for bluebird bio, Inc. (BLUE) compare to its historical average?